DObesity: Relationship between vitamin D deficiency, obesity and sclerostin as a novel biomarker of bone metabolism.
J Clin Transl Endocrinol
; 17: 100197, 2019 Sep.
Article
em En
| MEDLINE
| ID: mdl-31193780
ABSTRACT
AIM:
To study the relationship between obesity, insulin resistance, vitamin D deficiency and sclerostin as a bone biomarker. MATERIALS ANDMETHODS:
Cross-section study of 75 subjects grouped into 3 groups; obese (nâ¯=â¯31), overweight (nâ¯=â¯23) and normal (nâ¯=â¯21) subjects. Sclerostin, fasting insulin, fasting plasma glucose and 25(OH)D were measured and anthropometric measures were taken.RESULTS:
25(OH)D was lower in obese subjects than overweight and control groups (mean⯱â¯SD 5.27⯱â¯5.14 vs. 12.55⯱â¯6.99 vs.17.65⯱â¯4.07â¯ng/L, pâ¯<â¯0.001). Sclerostin was significantly lower in obese subjects versus the control (mean⯱â¯SD 1.02⯱â¯0.45 vs 1.58⯱â¯0.83â¯ng/mL, pâ¯=â¯0.014).CONCLUSION:
These results lead us to hypothesize that the relationship between sclerostin and Vitamin D levels has an important role in the link between obesity and bone metabolism. DObesity could be an active focus of research in the coming years.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article